Guideline for the management of fatigue in children and adolescents with cancer or pediatric hematopoietic cell transplant recipients: 2023 update

In this 2023 FN CPG update, changes from the 2017 CPG included two conditional recommendations regarding earlier discontinuation of empiric antibacterial therapy in clinically well and afebrile patients with low-risk FN if blood cultures remain negative at 48 hours despite no evidence of marrow recovery and pre-emptive antifungal therapy for IFD high-risk patients not receiving antimold prophylaxis. The panel also created a good practice statement to initiate FN CPG-consistent empiric antibacterial therapy as soon as possible in clinically unstable febrile patients.